M

Mersana Therapeutics
D

MRSN

9.73000
USD
-0.08
(-0.82%)
مغلق
حجم التداول
1,266
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
48,559,433
أصول ذات صلة الأخبار المقالات

العنوان: Mersana Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADCplatforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.